VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.

The findings further validate the potential of VERAXA's BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.

VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

For more details on the announcement, the full press release is available at https://ibn.fm/QiPhH. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.

Forward-looking statements in this article involve risks, uncertainties, and other factors that may cause actual results to differ materially. These include the risks set forth under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K or any updates in its Quarterly Reports on Form 10-Q and other SEC filings. Undue reliance should not be placed on these forward-looking statements, and the company undertakes no duty to update this information unless required by law.